191 related articles for article (PubMed ID: 19020383)
1. Hypopituitarism and HIV-infection: a new comorbidity in the HAART era?
Zirilli L; Orlando G; Diazzi C; Squillace N; Carani C; Guaraldi G; Rochira V
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):33-8. PubMed ID: 19020383
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone deficiency and human immunodeficiency virus.
Rochira V; Guaraldi G
Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):91-111. PubMed ID: 28477736
[TBL] [Abstract][Full Text] [Related]
3. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution.
Koutkia P; Eaton K; You SM; Breu J; Grinspoon S
AIDS; 2006 Apr; 20(6):855-62. PubMed ID: 16549969
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
[TBL] [Abstract][Full Text] [Related]
6. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
[TBL] [Abstract][Full Text] [Related]
7. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
Hirsch HH; Battegay M
Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
Bickel M; Zangos S; Lutz T; Eisen J; Knecht G; Goebel FD; Crespi CM; Jacobi V; Staszewski S; Klauke S
Scand J Infect Dis; 2008; 40(1):36-9. PubMed ID: 17852925
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients.
Guallar JP; Cano-Soldado P; Aymerich I; Domingo JC; Alegre M; Domingo P; Villarroya F; Javier Casado F; Giralt M; Pastor-Anglada M
Antivir Ther; 2007; 12(6):853-63. PubMed ID: 17926640
[TBL] [Abstract][Full Text] [Related]
10. [No improvement of lipodystrophy syndrome in an HIV-infected patient].
Lanzafame M; Faggian F; Lattuada E; Antolini D; Concia E
Recenti Prog Med; 2004 Jun; 95(6):312-3. PubMed ID: 15248414
[TBL] [Abstract][Full Text] [Related]
11. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
[TBL] [Abstract][Full Text] [Related]
12. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease.
Guaraldi G; Ventura P; Garlassi E; Orlando G; Squillace N; Nardini G; Stentarelli C; Zona S; Marchini S; Moriondo V; Tebas P
HIV Med; 2009 Jan; 10(1):28-34. PubMed ID: 19125962
[TBL] [Abstract][Full Text] [Related]
13. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
Taiwo B; Hicks C; Eron J
J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
[TBL] [Abstract][Full Text] [Related]
14. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
15. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity.
Villarroya F; Domingo P; Giralt M
Trends Pharmacol Sci; 2005 Feb; 26(2):88-93. PubMed ID: 15681026
[TBL] [Abstract][Full Text] [Related]
16. Update on HIV/HAART associated morphologic and metabolic abnormalities.
Falutz J
Forum Nutr; 2003; 56():158-62. PubMed ID: 15806844
[No Abstract] [Full Text] [Related]
17. [HIV infection: emerging issues and new challenges].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
[TBL] [Abstract][Full Text] [Related]
18. The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes.
Saumoy M; López-Dupla M; Veloso S; Alonso-Villaverde C; Domingo P; Broch M; Miranda M; Coll B; Saurí A; Vendrell J; Richart C; Vidal F
AIDS; 2008 Apr; 22(7):893-6. PubMed ID: 18427208
[TBL] [Abstract][Full Text] [Related]
19. Current clinical issues impacting the lives of patients living with HIV/AIDS.
Gallagher DM
J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S11-6. PubMed ID: 17275717
[TBL] [Abstract][Full Text] [Related]
20. [Cutaneous drug reactions in HIV-infected patients in the HAART era].
Blanes M; Belinchón I; Portilla J
Actas Dermosifiliogr; 2009 May; 100(4):253-65. PubMed ID: 19463228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
